

DIAGNOSIS AND TREATMENT OF BACTERIAL INFECTIONS | PART 1



Editors:

Mukesh Kumar Singh

Gurdeep Singh

Amrendra Pratap Yadav

Papiya Bigoniya

Bentham Books

Diagnosis and Treatment of Bacterial Infections

(Part 1)

Edited by

Mukesh Kumar Singh

*School of Pharmaceutical Sciences
Faculty of Pharmacy, IFTM University
Moradabad, Uttar Pradesh
India*

Gurdeep Singh

*School of Pharmaceutical Sciences
Lovely Professional University
Phagwara, Punjab
India*

Amrendra Pratap Yadav

*Department of Pharmacy
Meerut Institute of Technology
Meerut, Uttar Pradesh
India*

&

Papiya Bigoniya

*Cancer Biology Project
University of Westminster
London, UK*

Diagnosis and Treatment of Bacterial Infections - (*Part 1*)

Editors: Mukesh Kumar Singh, Gurdeep Singh, Amrendra Pratap Yadav & Papiya Bigoniya

ISBN (Online): 979-8-89881-345-1

ISBN (Print): 979-8-89881-346-8

ISBN (Paperback): 979-8-89881-347-5

© 2026, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore, in collaboration with Eureka Conferences, USA. All Rights Reserved.

First published in 2026.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.org.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.

No. 9 Raffles Place

Office No. 26-01

Singapore 048619

Singapore

Email: subscriptions@benthamscience.net



CONTENTS

FOREWORD	i
PREFACE	ii
LIST OF CONTRIBUTORS	iv
CHAPTER 1 INTRODUCTION AND HISTORICAL PERSPECTIVE ON BACTERIAL INFECTIONS	1
<i>Khushboo Gupta and Anshita Gupta</i>	
INTRODUCTION	1
Historical Background	2
Discovery of Bacteria	3
Pioneering Discoveries in Bacterial Infections	5
<i>The Plague</i>	5
<i>Tuberculosis</i>	5
<i>Cholera</i>	5
Clinical Manifestations of Bacterial Infections	6
Development of Antibacterial Treatments	7
Antimicrobial Resistance	8
Resistance Types	8
Approaches to Combat Antibiotic Resistance	9
Phage Therapy	10
Antimicrobial Stewardship Programs	10
New Antibiotic Classes	10
Impact on Public Health and Medicine	11
Bacterial Infection	11
Mechanisms of Bacterial Pathogenesis	14
<i>Bacterial Adhesion and Colonization</i>	14
<i>Invasion of Host Tissues</i>	14
<i>Toxin Production</i>	14
<i>Immune Evasion Strategies</i>	15
<i>Host-Pathogen Interactions</i>	15
Emerging Concepts in Bacterial Pathogenesis	16
CONCLUDING REMARKS	16
REFERENCES	17
CHAPTER 2 EPIDEMIOLOGY AND PATHOPHYSIOLOGY OF BACTERIAL INFECTIONS	21
<i>Alankar Shrivastav, Deepak Singh Chaudhary, Mukesh Kumar Singh, Shweta Verma, Navneet Verma and Arun Kumar Mishra</i>	
INTRODUCTION: BASIC BIOLOGY OF BACTERIA	21
Bacterial Cell Structure	22
Bacterial Growth and Reproduction	23
Historical Background of Bacterial Infections	25
<i>Early Understanding of Disease and Infections</i>	25
<i>The Middle Ages: Plagues and Pandemics</i>	26
<i>The Renaissance and the Birth of Microbiology</i>	26
<i>The 19th Century: Germ Theory and Medical Advances</i>	27
<i>Modern Challenges and Future Directions</i>	27
Major Types of Bacterial Infections	28
<i>Respiratory Infections</i>	28
<i>Gastrointestinal Infections</i>	29

Skin and Soft Tissue Infections	29
Systemic Infections	30
Zoonotic Bacterial Infections	30
MECHANISMS OF BACTERIAL PATHOGENICITY	35
Pathogenesis Overview	36
<i>Entry Points for Bacteria</i>	36
<i>Colonisation and Adherence to Host Tissues</i>	36
Virulence Factors	37
<i>Toxins</i>	37
<i>Enzymes that Facilitate Invasion</i>	37
<i>Evasion of the Immune System</i>	38
Host-Pathogen Interactions	38
<i>Immune Response to Bacterial Infections</i>	38
<i>Inflammatory Response and Cytokine Release</i>	39
<i>Bacterial Strategies to Overcome Host Defences</i>	39
CONCLUSION	39
FUTURE PERSPECTIVES	40
REFERENCES	40
CHAPTER 3 CONVENTIONAL THERAPY FOR BACTERIAL INFECTIONS	48
<i>Phool Chandra, Shahjad, Neetu Sachan, Arun Kumar and Nishat Fatima</i>	
INTRODUCTION	48
THE DISCOVERY OF ANTIBIOTICS	51
Alexander Fleming and Penicillin	52
Early Antibiotic Development	52
CLASSES OF ANTIBIOTICS	53
Beta-Lactams	53
<i>Penicillin</i>	53
<i>Case Studies</i>	54
Cephalosporins	55
<i>Spectrum of Activity</i>	55
<i>Clinical Applications</i>	56
<i>Role in Specific Patient Populations</i>	56
Carbapenems	57
<i>Role in Empiric Therapy</i>	58
Aminoglycosides	58
<i>Mechanism of Action and Spectrum of Activity</i>	58
<i>Clinical Indications</i>	59
<i>Specific Aminoglycoside Agents</i>	60
Tetracyclines	61
<i>Cellular Uptake</i>	61
<i>Effects on Mitochondrial Protein Synthesis</i>	62
<i>Inhibition of Matrix Metalloproteinases</i>	62
<i>Anti-Inflammatory and Immunomodulatory Effects</i>	62
<i>Resistance Mechanisms</i>	63
<i>Synergistic Effects</i>	63
<i>Clinical Indications</i>	63
<i>Emerging and Investigational Uses</i>	66
Macrolides	66
<i>Mechanism of Action</i>	66
<i>Spectrum of Activity</i>	67

<i>Clinical Indications</i>	67
<i>Specific Agents</i>	68
Quinolones	68
<i>Mechanism of Action</i>	69
<i>Spectrum of Activity</i>	69
Sulphonamides	71
<i>Mechanism of Action</i>	71
<i>Spectrum activity</i>	72
MECHANISMS OF ACTION	73
Inhibition of Cell Wall Synthesis	73
Inhibition of Protein Synthesis	74
Inhibition of Nucleic Acid Synthesis	75
Disruption of Cell Membrane Function	76
CLINICAL APPLICATIONS	77
Empiric therapy	77
Targeted Therapy	77
Targeted Therapy vs. Conventional Therapy	78
CHALLENGES IN CONVENTIONAL THERAPY	78
STRATEGIES TO COMBAT RESISTANCE	80
FUTURE DIRECTIONS	82
CONCLUSION	83
REFERENCES	84

CHAPTER 4 CHALLENGES AND CLASSICAL STRATEGIES FOR BACTERIAL INFECTIONS	100
<i>Arun K. Mishra, Harpreet Singh, S.K. Paliwal and Ajay Kumar Yadav</i>	
INTRODUCTION	100
IMPORTANCE OF CONVENTIONAL THERAPY IN BACTERIA-BORNE INFECTIONS	101
HOW BACTERIAL INFECTIONS OCCUR	103
Types of Bacterial Infections	104
Symptoms of Bacterial Infections	105
Diagnosis	105
Therapy	105
Preventative Measures	106
COMMON USES AND TYPES OF ANTIBIOTICS	106
Treatment Recommendations	108
MEDICAL TREATMENTS THAT ARE EMPLOYED TO TREAT INFECTIONS CAUSED BY BACTERIA	108
Bacterial Infection Diagnosis	108
Conventional Treatment for Bacterial Infections	109
Resistance to Antibiotics	109
Supportive Care	110
Preventive Measures	110
Long-Term Management	110
DEVELOPMENTS IN THE FIELD OF NEW ANTIBIOTICS	111
Drug Delivery Systems, Nanotechnology, and Emerging Therapies	113
Emerging Strategies in the Fight Against Bacterial Infections	114
CHALLENGES	115
CONCLUSION	115
ACKNOWLEDGEMENT	116

REFERENCES	116
CHAPTER 5 NOVEL STRATEGIES FOR TARGETING BIOFILM-ASSOCIATED BACTERIAL RESISTANCE	122
<i>Archana Bagre, Payal Saiju and Amrendra Pratap Yadav</i>	
INTRODUCTION	122
MICROBIAL BIOFILMS AND THEIR STRUCTURAL AND FUNCTIONAL ASPECTS	123
STAGES OF BACTERIAL BIOFILM FORMATION	124
Initial Attachment and Irreversible Adhesion	124
Matrix Formation	125
Microcolony Formation	125
Dispersion	125
QUORUM SENSING: ITS ROLE IN BACTERIAL BIOFILM DEVELOPMENT	125
DETECTION METHODS OF MICROBIAL BIOFILM	125
MECHANISMS OF ANTIBIOTIC RESISTANCE THROUGH BIOFILMS	127
BASIC STRATEGIES FOR TARGETING BIOFILM-ASSOCIATED BACTERIAL RESISTANCE	128
CONVENTIONAL APPROACHES FOR REMOVING BACTERIAL BIOFILMS	128
Limitations of Conventional Approaches for Removing Bacterial Biofilms	129
<i>Limited Antibiotic Penetration</i>	129
<i>Altered Microenvironment</i>	129
<i>Phenotypic Resistance and Tolerance</i>	130
<i>Inadequate Host Immune Clearance</i>	130
<i>Recurrence and Chronicity of Infections</i>	130
<i>Biofilm-Associated Resistance to Medical Devices</i>	130
<i>Development of Multidrug Resistance (MDR)</i>	130
NOVEL APPROACHES FOR REMOVING BACTERIAL BIOFILMS	131
SMART DELIVERY SYSTEM FOR BIOFILM-ASSOCIATED BACTERIAL INFECTION	132
Internal Stimuli-responsive Smart Drug Delivery System	132
<i>pH-responsive System</i>	132
<i>Enzyme-responsive System</i>	133
<i>Hypoxia-responsive System</i>	133
External Stimuli-responsive Smart Drug Delivery Systems	134
<i>Light-responsive System</i>	134
<i>Temperature-responsive System</i>	135
<i>Magnetic Field-responsive System</i>	135
CONCLUSION	135
REFERENCES	136
CHAPTER 6 CO-INFECTIONS AND OPPORTUNISTIC PATHOGENS IN AMELIORATING DISEASE OUTCOMES	140
<i>Rakesh Kumar, Vivek Raj, Vandana, Biplab Pal and Vikas Sharma</i>	
INTRODUCTION	141
Co-infections	141
Opportunistic Pathogens	141
The Epidemiological Significance	142
Paradox of Co-infections in Disease Amelioration	143
<i>Modulation of Immune Responses by Co-infections</i>	143
<i>Impact on Disease Progression and Outcomes</i>	143
MECHANISMS OF INTERACTION BETWEEN CO-INFECTIONS AND HOST IMMUNITY	144

Immunological Modulation by Co-infections	144
Pathogen-pathogen Interactions	145
Examples of Co-infections that Ameliorate Disease Outcomes	146
<i>Helminth Infections and Autoimmune Diseases</i>	146
<i>Measles Virus and Asthma</i>	146
<i>HIV and HTLV-1 Co-infection</i>	146
<i>GB Virus C and HIV</i>	147
<i>Plasmodium falciparum and Hepatitis B Virus</i>	147
CASE STUDIES: HOW OPPORTUNISTIC PATHOGENS INFLUENCE DISEASE	
OUTCOMES	147
Case Study 1: <i>Pseudomonas aeruginosa</i> in Cystic Fibrosis	148
Case Study 2: <i>Candida albicans</i> in HIV/AIDS	148
Case Study 3: <i>Aspergillus fumigatus</i> in Transplant Recipients	149
Case Study 4: <i>Clostridioides difficile</i> in Antibiotic-Associated Diarrhea	149
ROLE OF CYTOKINES AND CHEMOKINES	149
IMMUNE EVASION AND PATHOGEN PERSISTENCE	150
THERAPEUTIC IMPLICATIONS	150
Potential Benefits of Exploiting Co-infections	151
<i>Enhanced Immunological Response</i>	151
<i>Targeting Multiple Pathogens</i>	151
<i>Epidemiological Insights</i>	151
Challenges in Managing Co-infections	151
<i>Diagnostic Complexity</i>	151
<i>Treatment Interactions</i>	152
<i>Increased Morbidity and Mortality</i>	152
FUTURE DIRECTIONS AND RESEARCH GAPS IN PATHOGEN INTERACTIONS	152
Emerging Research on Pathogen Interactions	152
<i>Microbiome Studies</i>	152
<i>Genomics and Metagenomics</i>	153
<i>Pathogen-Pathogen Interactions</i>	153
Implications for Global Health and Disease Management	153
<i>Public Health Strategies</i>	153
<i>Therapeutic Approaches</i>	154
<i>Global Health Policies</i>	154
EXPERIMENTAL MODELS TO STUDY CO-INFECTION	155
CONCLUSION	156
REFERENCES	156
CHAPTER 7 UNRAVELING THE COMPLEXITIES OF COINFECTION DIAGNOSIS AND	
TREATMENT	160
<i>Monika Singh, Nitin Kumar, Sadish Kumar Shanmugam and Moumita Barman</i>	
INTRODUCTION	160
EPIDEMIOLOGY OF COINFECTIONS	162
CHALLENGES IN DIAGNOSIS	164
TREATMENT STRATEGIES	169
CASE STUDIES	171
FUTURE DIRECTIONS	171
CONCLUSION	172
ACKNOWLEDGEMENT	172
REFERENCES	172

CHAPTER 8 NOVEL DRUG DELIVERY SYSTEMS TO COMBAT ANTIMICROBIAL RESISTANCE	178
<i>Sanjay Kumar Gupta, Astha Verma, Akash Gupta, Sumit Sahu, Nousheen Khatoon, Anjila Firdous and Mohammad Adnan Raza</i>	
INTRODUCTION	179
Overview of Antimicrobial Resistance (AMR)	179
<i>Current Challenges in Treating Resistant Infections</i>	180
<i>Limitations of Current Systems</i>	180
Importance of NDDS	181
<i>Impact of NDDS</i>	183
Biological Barriers to Drug Delivery	184
Mechanisms of AMR	184
<i>Genetic and Biochemical Mechanisms</i>	186
Role of Biofilms and Efflux Pumps	187
Clinical Impact of AMR	189
Drug Delivery Systems to Combat AMR: Overview of Drug Delivery Concepts	189
Importance of Targeted and Controlled Release	193
<i>Improved Drug Efficacy at Infection Sites</i>	193
<i>Reduced Side Effects and Toxicity</i>	193
<i>Prevention of AMR Development</i>	193
<i>Overcoming Drug Resistance Mechanisms</i>	194
<i>Extended Drug Activity and Improved Patient Compliance</i>	194
<i>Minimizing Overuse of Antibiotics</i>	194
<i>Enhanced Penetration of Hard-to-Reach Areas</i>	194
<i>Combination Therapies</i>	195
<i>Advantages of NDDS in Combating AMR</i>	195
Stimuli-Responsive Drug Delivery Systems	200
<i>Exogenous Stimuli-Responsive Antibiotic Drug-Delivery Systems</i>	200
<i>Magnetic Release for Biofilm Eradication</i>	201
Endogenous Stimuli-Responsive Antibiotic Drug-Delivery Systems	201
<i>pH-Responsive Delivery Systems</i>	201
<i>Enzyme-Responsive Systems</i>	202
<i>Light and Magnetic Field-Responsive Systems</i>	202
Integration with Antimicrobial Peptides	203
<i>Synergistic Effects of NDDS and Antimicrobial Peptides</i>	203
Biofilm-Targeted Delivery Systems	204
<i>Challenges of Biofilm-Associated Infections</i>	204
<i>Strategies to Combat Biofilms</i>	205
Case Studies	207
Applications	208
CONCLUSION	208
REFERENCES	209
SUBJECT INDEX	218

FOREWORD

It is my distinct honour to have the opportunity to contribute the foreword for *Diagnosis and Treatment of Bacterial Infections, Part I*. This comprehensive text will examine bacterial infections from historical, epidemiological, and therapeutic perspectives. The authors discuss conventional and challenging ways to manage bacterial infections and explore cutting-edge ways that clinicians can manage antibiotic-resistant bacteria using targeted treatments for biofilm-associated resistant pathogens and novel drug delivery methods. The section on coinfections and opportunistic pathogens discusses how difficult it can be for clinicians to manage complex clinical cases and how precise and accurate diagnosis and treatment of patients is critical.

This Part will be an essential resource for researchers, medical professionals, and students, providing an overview of bacterial infections and current strategies for reducing the impact of antimicrobial resistance through advanced diagnostic and therapeutic options. I congratulate the authors for their impressive effort and wish them all the best in achieving their goal of improving understanding and managing bacterial infections.

Ranjit Singh
Shobhit University
Gangoh, Uttar Pradesh, India

PREFACE

Bacterial infections are a global health issue. Despite many advances in the fields of science, medicine, diagnostic methods, and treatment with anti-microbials, bacterial infections remain a significant contributor to morbidity and mortality around the world. The emergence of large numbers of resistant strains of bacteria, persistent problems due to biofilm infections, and increasing awareness of co-infections and opportunistic pathogens have created an urgent demand for current, linked, evidence-based information. The first part of *Bacterial Infections: Diagnosis and Treatment* has been compiled to provide timely and relevant information about bacterial infections, from basic principles to new therapies.

The introduction of this part provides a historical perspective of bacterial infections, presenting the major events that have contributed to the current understanding and clinical management of bacterial infections. Following the introduction, the part presents an extensive description of the epidemiology and pathophysiology of bacterial infections. A major focus of this section will be to discuss the global impact of bacterial infections, how bacteria are transmitted between people, the interactions that occur between bacteria and their human host, and how bacteria are able to produce disease. The last section of this part reviews the existing antibacterial medications and treatment protocols; this review provides a robust clinical basis to support the subsequent sections of the work.

The concluding chapters are intended to bring together a variety of innovative drug delivery systems, as well as new, sophisticated antimicrobial therapeutic platforms that are intended to increase the effectiveness of antimicrobial medications while simultaneously decreasing the likelihood of developing antimicrobial resistance. It has been constructed in such a way that the initial foundation laid will be further complemented by recent advances in science and technology, thus providing the most comprehensive source available for infection disease clinicians, researchers, academics, pharmaceutical scientists, and graduate students involved in infectious disease research and clinical practice.

Part II of the series provides information that supports both the information in Part I and some of the advances in integrative, genetic, immunological, and digital technologies that could support the treatment of bacterial infections in the future, as well as addresses some of the issues of increasing bacterial resistance to current antibiotic therapies.

Mukesh Kumar Singh
School of Pharmaceutical Sciences
Faculty of Pharmacy, IFTM University
Moradabad, Uttar Pradesh
India

Gurdeep Singh
School of Pharmaceutical Sciences
Lovely Professional University
Phagwara, Punjab
India

iii

Amrendra Pratap Yadav
Department of Pharmacy
Meerut Institute of Technology
Meerut, Uttar Pradesh
India

&

Papiya Bigoniya
Cancer Biology Project
University of Westminster
London, UK

List of Contributors

Anshita Gupta	Department of Pharmacy, Gurughasi Das Vishwavidyalaya, Bilaspur (C.G.), India
Alankar Shrivastav	Faculty of Pharmacy, IFTM University, Moradabad, 244001, U.P., India
Arun Kumar	Department of Pharmacology, Global Institute of Pharmaceutical Education and Research, Kashipur, 244713, Uttarakhand, India
Arun K. Mishra	SOS School of Pharmacy, IFTM University, Moradabad, 244102, India
Ajay Kumar Yadav	School of Pharmaceutical Sciences, CSJM University, Kanpur, 208024, India
Archana Bagre	Department of Pharmaceutics, Lakshmi Narain College of Pharmacy, Bhopal, Madhya Pradesh, India
Amrendra Pratap Yadav	Department of Pharmacy, Meerut Institute of Technology, Meerut, Uttar Pradesh, India
Astha Verma	Department of Pharmaceutics, Shri Rawatpura Sarkar Institute of Pharmacy, Chhattisgarh, 490024, India
Akash Gupta	Department of Pharmacology, Rungta College of Pharmaceutical Sciences and Research, Chhattisgarh, 490024, India
Anjila Firdous	Department of Pharmacology, Rungta College of Pharmaceutical Sciences and Research, Chhattisgarh, 490024, India
Biplab Pal	School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, 144411, Punjab, India
Deepak Singh Chaudhary	Faculty of Pharmacy, IFTM University, Moradabad, 244001, U.P., India
Harpreet Singh	School of Pharmaceutical Sciences, IFTM University, Moradabad, 2444102, India
Khushboo Gupta	Faculty of Pharmacy, Kalinga University, Naya Raipur (C.G), India
Mukesh Kumar Singh	Faculty of Pharmacy, IFTM University, Moradabad, 244001, U.P., India
Monika Singh	Department of Pharmacology, I.T.S College of Pharmacy, Ghaziabad, India
Moumita Barman	Department of Pharmaceutics, I.T.S College of Pharmacy, Ghaziabad, India
Mohammad Adnan Raza	Department of Pharmacology, Rungta College of Pharmaceutical Sciences and Research, Chhattisgarh, 490024, India
Navneet Verma	Faculty of Pharmacy, IFTM University, Moradabad, 244001, U.P., India
Neetu Sachan	Department of Pharmaceutical Sciences, School of Pharmaceutical & Biological Sciences, Harcourt Butler Technical University (HBTU), Kanpur, 208002, Uttar Pradesh, India
Nishat Fatima	Department of Pharmacology, MIT College of Pharmacy, Moradabad, 244001, Uttar Pradesh, India
Nitin Kumar	Department of Pharmacognosy, Meerut Institute of Technology, Meerut, India
Nousheen Khatoon	Department of Pharmacology, Rungta College of Pharmaceutical Sciences and Research, Chhattisgarh, 490024, India

Phool Chandra	Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad, 244001, Uttar Pradesh, India
Payal Saiju	Department of Pharmaceutics, Lakshmi Narain College of Pharmacy, Bhopal, Madhya Pradesh, India
Rakesh Kumar	School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, 144411, Punjab, India
Shweta Verma	Faculty of Pharmacy, IFTM University, Moradabad, 244001, U.P., India
Shahjad	Department of Pharmacology, Global Institute of Pharmaceutical Education and Research, Kashipur, 244713, Uttarakhand, India
S.K. Paliwal	Department of Pharmacy, Banasthali Vidyapith, Banasthali, 304022, India
Sadish Kumar Shanmugam	Department of Pharmaceutical Chemistry, I.T.S College of Pharmacy, Ghaziabad, India
Sanjay Kumar Gupta	Department of Pharmacology, Rungta College of Pharmaceutical Sciences and Research, Chhattisgarh, 490024, India
Sumit Sahu	Department of Pharmacology, Rungta College of Pharmaceutical Sciences and Research, Chhattisgarh, 490024, India
Vivek Raj	Department of Biotechnology, Patna Women's College, Patna, Bihar, India
Vandana	Indus Institute of Management, Indus University, Rancharda via Thaltej, Ahmedabad, 382114, Gujarat, India
Vikas Sharma	School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, 144411, Punjab, India

CHAPTER 1

Introduction and Historical Perspective on Bacterial Infections

Khushboo Gupta^{1,*} and Anshita Gupta²

¹ Faculty of Pharmacy, Kalinga University, Naya Raipur (C.G), India

² Department of Pharmacy, Gurughasi Das Vishwavidyalaya, Bilaspur (C.G.), India

Abstract: Pathogenic microorganisms that cause bacterial illnesses have a profound impact on community health, medicine, and the overall humanity. These infections, which can range in severity from minor ailments to fatal conditions, have influenced the development of treatments and spurred advances in medical knowledge. Hippocrates, the Greek physician, and Galen, the Roman scholar, detailed a number of diseases that could be caused by bacteria. The discoveries made by Louis Pasteur and Robert Koch during the 19th century were crucial because they established a framework for connecting particular bacteria to particular diseases, greatly expanding our knowledge of bacterial pathogenesis. Vaccines and antibiotics were also industrialized during this time, revolutionizing the management and avoidance of microbial diseases. Alexander Fleming's discovery of penicillin in the 20th century marked the dawn of the antibiotic era, revolutionizing the treatment of bacterial illnesses and saving countless lives. Nonetheless, the emergence of antibiotic resistance in recent times has presented novel obstacles, stimulating continuous investigation into substitute therapies and pre-emptive actions.

Keywords: Antibiotic resistance, Bacterial infections, Pathogenic microorganisms.

INTRODUCTION

Infections with bacteria rank among the biggest health risks in human history. Pathogenic bacteria are the source of these infections. They enter the body and cause a wide range of illnesses, from minor to fatal. In addition to advancing our knowledge of these microbes, research on bacterial infections influences public health and contemporary medicine [1]. Globally, bacterial infections, which can range from minor localized infections to serious systemic disorders, are a major source of morbidity and mortality. The immune system of the host and the invasive bacteria interact intricately throughout the development of bacterial

* Corresponding author **Khushboo Gupta**: Faculty of Pharmacy, Kalinga University, Naya Raipur (C.G), India; E-mail:khushboo.gupta@kalingauniversity.ac.in

infections [2]. The study of bacterial infections has evolved considerably since the discovery of bacteria by Antoine van Leeuwenhoek in the 17th century, leading to critical advancements in understanding the pathogenesis, diagnosis, and treatment of these infections. This chapter gives a thorough review of the origins, development, and effects of bacterial diseases on society in addition to charting their discovery and progression [3, 4]. Research on bacterial infections has grown significantly in the last few decades, impacting not only the science of microbiology but also clinical practices and public health policies [5].

Historical Background

In the past, people had a misunderstanding about the origins of diseases and frequently linked them to supernatural forces or the wrath of gods. While diseases and infections are mentioned in ancient literature like the Egyptian Ebers Papyrus (c. 1550 BCE), the idea that microbes are the cause was not recognized.

Previous Hypotheses and Views: Hippocrates and other Greek physicians postulated that an imbalance in the body's "humours," or bodily fluids, was the root cause of sickness. Before scientific research started to question these ideas during the Renaissance, this theory dominated Western medicine for centuries [6, 7]. Table 1 represents a timeline of bacterial discoveries with significance.

Table 1. A timeline of bacterial infection discoveries.

S. No	Time Period	Event	Significance
1	Ancient Times	Early Recognition of Infections	Ancient Egyptians and Greeks noticed infections from wounds.
3	1676	Discovery of Bacteria	Antonie van Leeuwenhoek observed bacteria using a microscope.
4	19 th Century	Germ Theory of Disease	Proposed by Louis Pasteur and Robert Koch; established bacteria as causes of disease.
5	1854	Cholera Outbreak in London	John Snow traced the outbreak to contaminated water, foundational for epidemiology.
6	1876	<i>Anthrax bacillus</i> Identified	Robert Koch identified <i>Bacillus anthracis</i> as the cause of anthrax, establishing Koch's postulates.
7	1882	Discovery of <i>Tuberculosis bacterium</i>	Robert Koch identified <i>Mycobacterium tuberculosis</i> as the cause of tuberculosis.
8	1928	Discovery of Penicillin	Alexander Fleming discovered penicillin, the first antibiotic, revolutionizing the treatment of bacterial infections.
9	1940s	Widespread Use of Antibiotics	Penicillin and other antibiotics began to be mass-produced and used widely, drastically reducing bacterial infection mortality.

(Table 1) cont....

S. No	Time Period	Event	Significance
10	1980s-2000s	Rise of Antibiotic Resistance	Overuse and misuse of antibiotics led to the emergence of resistant bacteria such as MRSA.
11	21 st Century	Modern Challenges	Ongoing challenges include antibiotic resistance, the development of new antibiotics, and understanding bacterial evolution.

Discovery of Bacteria

Antony van Leeuwenhoek and the First Microscope: In the latter part of the 17th century, Dutch microscopist Antony van Leeuwenhoek discovered bacteria when he used his handmade microscope to view “animalcules.” His findings established the field of microbiology, even though he was unaware of its importance.

Louis Pasteur and Germ Theory

Throughout the history of science and medicine, Louis Pasteur, a French chemist and microbiologist, has had a significant impact. By developing the germ theory, his groundbreaking work in the middle of the 19th century established the groundwork for contemporary microbiology and the comprehension of infectious diseases. By proving that bacteria are the root cause of many diseases, this hypothesis transformed medicine and gave rise to significant improvements in both public health and medical care [8 - 10].

With his research on fermentation, Pasteur laid the groundwork for the germ theory. He was tasked with looking into the brewing industry's alcohol deterioration in the 1850s. Pasteur discovered that different kinds of microbes created different fermentation products and that microorganisms were responsible for the fermentation process. He noticed that when undesirable microbes were introduced into the brewing process, unwanted fermentation happened. Following this observation, Pasteur postulated that bacteria were active actors in biochemical processes rather than merely byproducts of decomposition. He postulated that if germs could alter organic things, they could also be in charge of infecting people and other animals with diseases [11, 12]. The germ theory of disease was founded on Pasteur's work on fermentation, and his experiments refuted spontaneous generation. He postulated that a variety of ailments were brought on by microbes, or “germs.” Contrary to the miasma theory, which held that illnesses were brought on by “bad air” or miasmas, this concept was innovative.

The germ theory proposed by Pasteur had significant medical and public health ramifications. It was proposed that sickness may be stopped by limiting the

CHAPTER 2

Epidemiology and Pathophysiology of Bacterial Infections

Alankar Shrivastav^{1,*}, Deepak Singh Chaudhary¹, Mukesh Kumar Singh¹, Shweta Verma¹, Navneet Verma¹ and Arun Kumar Mishra¹

¹ Faculty of Pharmacy, IFTM University, Moradabad, U.P. 244001, India

Abstract: Bacterial infections remain a significant cause of global morbidity and mortality, with their prevalence influenced by geography, population dynamics, and medical interventions. The rise in healthcare-associated infections, as well as emerging and re-emerging pathogens, has altered the landscape of bacterial disease. This review focuses on current trends in bacterial infections, particularly those caused by *Mycobacterium tuberculosis*, *Escherichia coli*, and *Staphylococcus aureus*.

Understanding the pathophysiology of bacterial infections is critical for developing effective prevention and treatment strategies. Bacteria have evolved sophisticated mechanisms to evade the host immune system, including toxin production, tissue invasion, and immune manipulation. Quorum sensing plays a key role in coordinating pathogenic behaviour, especially within biofilms, which promote genetic variation and antibiotic resistance. A deeper insight into these biological processes, combined with epidemiological data, is essential for enhancing disease surveillance, refining therapeutic approaches, and reducing the global burden of bacterial infections.

Keywords: Bacteria, Bacterial infection, Epidemiology, Pathogenesis.

INTRODUCTION: BASIC BIOLOGY OF BACTERIA

The most diverse and fundamental biological entities on the planet are bacteria. These unicellular microorganism are strikingly different from other living organisms [1]. They are prokaryotic, meaning their cells lack a true nucleus and contain prokaryotic organelles and structures surrounded by a membrane. Bacteria play essential roles in ecosystems, often cohabiting with other organisms and enabling crucial ecological processes, despite their ancient reputation as causes of disease [2].

* Corresponding author Alankar Shrivastav: Faculty of Pharmacy, IFTM University, Moradabad, U.P. 244001, India; E-mail: alankar1994.ss@gmail.com

Bacterial Cell Structure

Bacteria have a minimal yet incredibly functional cellular design that helps them grow in diverse environments. A bacterial cell includes the following components [3].

The cell envelope consists of the cell wall, plasma membrane, and an outer membrane in some species. A bacterial cell's plasma membrane consists of a phospholipid bilayer, which is very important for controlling the passage of substances in or out of the cell. It gives the cell its shape and provides structural support surrounding the plasma membrane. Based on the composition of the cell wall, this study will segregate bacteria into two groups: Gram-positive and Gram-negative [4]. The crystal violet is retained based on the thick peptidoglycan surrounding Gram-positive bacteria. In comparison, the outermost layer of gram-negative bacteria comprises lipopolysaccharide and peptidoglycan, which are the thinnest. Safranin may be employed as a counterstain for the bacteria since it is also red. Some bacteria also have an optional second line of defence in the form of a shield outside their cell wall called a capsule. The capsule helps the bacteria stick to surfaces and escape from immune system detection [5].

The gel-like material that is found inside the plasma membrane is home to cell structures, waste products, nutrients, enzymes, and water. The nucleoid, a component of the bacterial cytoplasm, contains the lone circular DNA molecule that makes up the bacterial chromosome. Unlike eukaryotes, bacteria do not have a membrane-bound nucleus; hence, their genetic material is not segregated into a separate compartment [6]. The molecular machinery responsible for producing proteins, known as ribosomes, is found within the cytoplasm of bacteria. These 70S ribosomes are composed of the 30S and the 50S subunits. Inclusion bodies are additional basic structures seen in bacteria. These are granules that are stored in the cytoplasm and contain nutrients or building blocks such as polyphosphate, sulfur granules, or glycogen. Furthermore, some bacteria have tiny, circular DNA molecules called plasmids that reside apart from chromosomal DNA [7]. Plasmids can carry genes that provide advantageous traits to bacteria, such as antibiotic resistance, virulence factors, or distinct metabolic pathways [8].

Flagella are extended, whip-like appendages that aid in movement. One or more flagella, positioned at different locations on the cell surface, can be seen on bacteria [9]. Pili and Fimbriae are hair-like projections that facilitate bacterial adhesion to one another and surfaces. Pili are also involved in conjugation, a procedure that consists of the exchange of genetic material between bacterial cells [10].

Bacterial Growth and Reproduction

Bacteria reproduce primarily through a process called binary fission, where a single cell divides into two genetically identical daughter cells. The basic steps of binary fission are shown in Fig.(1)[11 - 13]:




Fig. (1). Steps involved in bacterial growth and reproduction.

1. **DNA Replication:** The bacterial chromosome is replicated, ensuring each daughter cell receives an identical copy.
2. **Cell Elongation:** The cell elongates, and the newly synthesised DNA molecules move to opposite poles of the cell.
3. **Septum Formation:** A septum, or dividing wall, forms in the centre of the cell.
4. **Cell Division:** The septum completes the division, resulting in two separate cells.

Conventional Therapy for Bacterial Infections

Phool Chandra^{1,*}, Shahjad², Neetu Sachan³, Arun Kumar² and Nishat Fatima⁴

¹ Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad-244001, Uttar Pradesh, India

² Department of Pharmacology, Global Institute of Pharmaceutical Education and Research, Kashipur-244713, Uttarakhand, India

³ Department of Pharmaceutical Sciences, School of Pharmaceutical & Biological Sciences, Harcourt Butler Technical University (HBTU), Kanpur-208002, Uttar Pradesh, India

⁴ Department of Pharmacology, MIT College of Pharmacy, Moradabad-244001 Uttar Pradesh, India

Abstract: This chapter explores the evolution and significance of conventional therapy for bacterial infections, with a focus on antibiotics as cornerstone treatments. It provides a comprehensive analysis of the mechanisms by which major antibiotic classes function, such as inhibition of cell wall synthesis, protein synthesis, and DNA replication, as well as their bacterial targets and clinical uses. It traces the development of antibiotic families like beta-lactams, aminoglycosides, tetracyclines, and quinolones. It also emphasizes the challenges of antibiotic resistance and outlines new therapeutic strategies. The chapter concludes by highlighting the need for balanced empirical and targeted therapies and stresses ongoing innovation to combat antimicrobial resistance (AMR).

Keywords: Aminoglycosides, Antibiotic resistance, Antibiotics, Beta-lactams, Bacterial infections, Conventional therapy, Infectious disease management, Penicillin, Quinolones, Tetracyclines.

INTRODUCTION





Conventional therapy for bacterial infections involves the administration of antibiotics, which have been the mainstay in clinical practices for combating bacterial infections. However, resistance to bacteria has arisen as a result of the misuse of antibiotics and biofilm formation, complicating treatment strategies [1]. To address these challenges, novel approaches such as metal nanoparticles, antimicrobial peptides, and phage therapy have been explored as alternatives to traditional antibiotics [2]. Furthermore, a systematic approach incorporating

* Corresponding author Phool Chandra: Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad-244001, Uttar Pradesh, India; E-mail: profpcpatel@gmail.com

topical and systemic antimicrobial agents, steroid drugs, and the selective decontamination of the digestive tract (SDD) method is essential for preventing infection and eliminating pathogens in severely sick patients [3]. As discussed in various research papers, conventional therapy for bacterial infections involves the use of antibiotics, which have been the mainstay in medical settings for many years. However, antimicrobial resistance (AMR) has emerged as a result of antibiotic misuse and biofilm-related infections, posing significant challenges in treatment. To combat these issues, alternative approaches such as metal nanoparticles, antimicrobial peptides, and phage therapy have been explored as potential solutions to address AMR and biofilm formation. Additionally, strategies like systemic and local antibiotic treatments, non-fouling surfaces, and the application of antibiotics and nanoparticles like silver and zinc oxide have been employed to prevent infections related to biomedical devices and implants [4]. The history of conventional therapy for bacterial infections is marked by significant milestones. The discovery of sulphonamides and penicillin in the 1930s and 1940s, respectively, revolutionized the treatment of bacterial infections [5]. These breakthroughs were the result of systematic investigations into chemicals with antibacterial properties, setting the stage for the antibiotic era in modern medicine, as shown in Table 1 [6]. Table 1 summarizes key milestones in antibiotic development from 1909 to the present. It highlights the introduction of major antibiotic classes such as sulfonamides, beta-lactams, aminoglycosides, and quinolones, along with the decades marked as the “golden age” of antibiotic discovery. The timeline also notes structural classifications and unique breakthroughs like carbapenems and lipopeptides.

Following this, additional families of antibiotics were developed, including oxazolidinones and lipopeptides, which significantly expanded the therapeutic options against resistant bacterial strains. Oxazolidinones, such as linezolid, act by inhibiting the initiation of bacterial protein synthesis through binding to the 50S ribosomal subunit, making them effective against Gram-positive organisms, including methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant Enterococcus (VRE). Lipopeptides, like daptomycin, disrupt the bacterial cell membrane potential, leading to rapid depolarization and cell death. These agents are crucial in treating complicated skin and bloodstream infections caused by multidrug-resistant pathogens [7]. Despite the success of antibiotics, the overuse of these drugs has caused an increase in resistance to antibiotics, prompting the exploration of natural compounds with antibacterial effects as potential alternatives to traditional antibiotics. Additionally, historical records suggest that radiation therapy was once considered an effective treatment for infections before the widespread use of antibiotics, demonstrating how the field of treatments for bacterial infections has evolved over time [8].

Table 1. Evolution of antibiotics.

Year	Antibiotics	Chemical Structure	Ref.
1909	Arsphenamine (First sulphur drug)	 Arsphenamine	[21]
1928	Penicillin (The most important drug of the last century)	 Penicillin	[22]
1932	Prontosil (The most important drug of the last century)	 Prontosil	[23]
1943	Streptomycin (First aminoglycoside)	 Streptomycin	[24]

Challenges and Classical Strategies for Bacterial Infections

Arun K. Mishra^{1*}, Harpreet Singh², S.K. Paliwal³ and Ajay Kumar Yadav⁴

¹ SOS School of Pharmacy, IFTM University, Moradabad-244102, India

² School of Pharmaceutical Sciences, IFTM University, Moradabad-2444102, India

³ Department of Pharmacy, Banasthali Vidyapith, Banasthali-304022, India

⁴ School of Pharmaceutical Sciences, CSJM University, Kanpur-208024, India

Abstract: Conventional therapy, specifically the administration of antibiotics, plays a vital role in combating bacterial infections. The significance of this approach lies in its ability to efficiently eradicate bacteria from the body, prevent infection dissemination, and reduce the likelihood of complications or mortality. Antibiotics are specifically formulated to selectively attack bacteria, either by directly causing their death (bactericidal) or by impeding their growth and ability to reproduce (bacteriostatic). This approach's focused nature makes antibiotics highly effective in treating bacterial infections. Antibiotics are categorised into distinct classes that function through diverse mechanisms, including disruption of the bacterial cell wall, inhibition of protein synthesis, or interference with DNA replication. This particular type of variety enables customised treatment based on the specific type of bacteria and the location of the infection. Antibiotics rapidly eradicate bacteria, thereby mitigating the transmission of infectious diseases to others. It is especially crucial in extremely contagious diseases, such as bacterial meningitis, tuberculosis, or specific sexually transmitted infections. Unaddressed bacterial infections have the potential to disseminate throughout the body, resulting in serious complications such as sepsis, organ impairment, or long-term illness. Traditional treatment methods help to control the infection, thereby decreasing the likelihood of such consequences.

Keywords: Antibiotics, Bacteria, Conventional therapy, Infections.

INTRODUCTION

Bacterial infections such as sepsis, bacterial pneumonia, and meningitis can pose a serious risk to one's life [1]. Antibiotics can be crucial in these instances, as they swiftly eradicate the bacteria responsible for the infection, potentially saving lives [2]. The advent of antibiotics in the 20th century significantly diminished the

* Corresponding author Arun K. Mishra: SOS School of Pharmacy, IFTM University, Moradabad-244102, India; E-mail: arun_azam@rediffmail.com

mortality rates linked to bacterial infections, which had previously been a prominent global cause of death [3]. Appropriate use of antibiotics guarantees the eradication of all the bacteria responsible for the infection. Insufficient administration or improper use of antibiotics can lead to the survival of bacteria that are resistant to the drugs. These bacteria can then reproduce and cause more severe infections that are more difficult to treat [4]. When conventional therapy is prescribed and followed correctly, it reduces this risk to a minimum. Conventional therapy is a component of larger initiatives aimed at encouraging responsible antibiotic use, thereby mitigating the emergence of antibiotic-resistant bacteria, which pose a growing public health risk [5]. Antibiotics expedite the healing process by efficiently combating bacterial infections, resulting in a shorter duration of illness and alleviating associated discomfort [6]. Certain bacterial infections, if not treated, can result in long-term health conditions. Untreated strep throat can result in the development of rheumatic fever, a condition that can cause long-term heart damage [7]. Antibiotics aid in the prevention of such complications. In the field of public health, conventional therapy is critical for managing outbreaks of bacterial infections. Healthcare providers can mitigate broader community transmission by providing treatment to affected individuals. The availability and use of antibiotics have had a significant impact on global health, enhancing both life span and quality of life through the management and eradication of previously devastating infections [8]. Conventional therapy, specifically antibiotics, is crucial for efficiently eradicating bacteria, halting the transmission of infections, preserving lives, and expediting the healing process. Additionally, it plays a vital role in combating antibiotic resistance, which is essential for preserving the efficacy of these life-saving therapies for future generations [9]. The use of conventional therapy in treating bacterial infections has led to significant improvements in patient outcomes, decreased mortality rates, and effectively tackled issues such as antibiotic resistance. Bacterial infections are pathogenic conditions resulting from the invasion, replication, and subsequent harm inflicted by detrimental bacteria on bodily tissues [4]. Bacteria are minuscule, unicellular organisms that inhabit diverse environments, such as soil, water, and the human body. Although numerous bacteria are innocuous or even advantageous, certain ones can induce illnesses upon infiltrating the body [10].

IMPORTANCE OF CONVENTIONAL THERAPY IN BACTERIA-BORNE INFECTIONS

The present chapter highlights the crucial role of antibiotics in the treatment of bacterial infections, which are considered a standard form of therapy (Fig. 1). Antibiotics, which are fundamental in traditional treatment, are specifically formulated to exterminate bacteria or impede their proliferation [9]. These treatments specifically attack the bacterial cells, making them extremely efficient in addressing various bacterial infections, ranging from minor skin infections to severe conditions such as sepsis and meningitis [9].




Fig. (1). Elimination of bacteria-borne infections.

Conventional antibiotics have undergone thorough research and testing, resulting in consistent and predictable results when used to treat bacterial infections. The predictability is crucial in clinical settings, as it guarantees that patients are administered treatments with a high probability of success [11]. Unaddressed bacterial infections can result in grave complications, such as the dissemination of the infection to other body regions (such as bacteremia or sepsis), long-term health problems, or even mortality [12]. Conventional therapy effectively eradicates the infection, thereby minimising the likelihood of such consequences. Untreated bacterial infections, including bacterial pneumonia, tuberculosis, and bacterial meningitis, have the potential to be lethal if not promptly treated with antibiotics. Conventional therapy is crucial for preserving lives, especially in cases of severe or rapidly advancing infections [2].

Certain bacterial infections, such as tuberculosis or bacterial meningitis, have a high level of contagiousness. Conventional therapy plays a crucial role in preventing the transmission of infections to others and safeguarding public health by effectively treating infected individuals. The extensive utilisation of antibiotics in the past has effectively managed bacterial outbreaks and mitigated diseases that previously caused widespread epidemics [13].

Novel Strategies for Targeting Biofilm-Associated Bacterial Resistance

Archana Bagre^{1,*}, Payal Saiju¹ and Amrendra Pratap Yadav²

¹ Department of Pharmaceutics, Lakshmi Narain College of Pharmacy, Bhopal, Madhya Pradesh, India

² Department of Pharmacy, Meerut Institute of Technology, Meerut, Uttar Pradesh, India

Abstract: Biofilm is a 3D structure formed by surface-associated clusters of microbial cells, which are encased in an extracellular polymeric substance (EPS) called the matrix. Infections associated with biofilms can be irreversible and life-threatening. Understanding biofilm formation, its propagation, the mechanism of resistance development, and its identification/detection is crucial in today's context. We discuss in detail the reasons for the development of drug resistance mechanisms by highlighting the important structural and functional aspects of microbial biofilms. Exploring various biochemical factors, molecular mechanisms, and changes in host environments that contribute to the development of bacterial resistance within biofilms is essential for developing novel treatment strategies for biofilm eradication. The detailed revelation of multidisciplinary strategies for biofilm destruction necessitates the identification of target sites within the biofilm. Recent advancements in drug delivery systems have led to the use of numerous biofilm-fighting strategies. Therapeutic strategies include the use of nanotechnology, bioengineering, smart delivery systems that respond to stimuli, and modifications to particle surfaces, such as mixing with organic materials, among others. Therefore, this chapter is an effort to give an overview of current therapeutic strategies and future perspectives for the treatment of biofilm-associated infections.

Keywords: Biofilms, EPS Matrix, Novel drug delivery system, Resistance.

INTRODUCTION

Biofilm is a collection of microorganisms that adhere to the surface and nest within an extracellular polymeric matrix. It is primarily found in bacteria but may also be present in fungi, viruses, protozoa, or other microbes. It is a complicated arrangement of proteins, polysaccharides, and DNA in an extracellular polymeric matrix that protects bacteria [1]. Due to the complex structure of biofilms in comparison to the microbe, it can produce an unresponsive host immune system

* Corresponding author Archana Bagre: Department of Pharmaceutics, Lakshmi Narain College of Pharmacy, Bhopal, Madhya Pradesh, India; E-mail: pataskar.archana2609@gmail.com

that leads to the development of antibiotic resistance. Anton Van Leeuwenhoek defined biofilm as a cluster of bacteria that adheres to an inert or living surface in a hydrated polymeric matrix [2]. Recently, biofilms have gained significant attention due to their involvement in over 80% of chronic infections, particularly those associated with medical devices, chronic wounds, and respiratory illnesses. Within biofilms, bacteria exhibit enhanced resistance to antibiotics that is up to 1,000 times greater than that of their planktonic counterparts due to factors such as limited drug penetration, altered metabolic activity, activation of efflux pumps, and the presence of dormant persister cells. These properties make conventional antibiotic therapies largely ineffective, positioning biofilm research at the forefront of antimicrobial resistance (AMR) studies [3, 4].

Currently, biofilms are extensively used as models for antimicrobial drug screening and the development of anti-biofilm coatings, hydrogels, and vaccines. They more accurately mimic the *in vivo* conditions of chronic infections compared to traditional planktonic models. Moreover, biofilm studies have shed light on quorum sensing (QS) mechanisms that regulate virulence and resistance, offering new targets for non-lethal anti-virulence therapies. Understanding biofilm structure and behaviour is therefore essential for developing novel therapeutic strategies and medical materials aimed at overcoming biofilm-associated resistance [5, 6].

MICROBIAL BIOFILMS AND THEIR STRUCTURAL AND FUNCTIONAL ASPECTS

Biofilms are self-formed biopolymer matrices that contain exopolysaccharides (EPS), extracellular DNA (e-DNA), and extracellular proteins. The exopolysaccharides provide a strong and sticky structure for forming biofilms, which can be created inside or outside of cells; examples of important polysaccharides include alginate in *P. aeruginosa* and colonic acid in *E. coli*. Exopolysaccharides act as “molecular glue” and create specific changes in gene expression, such as the release of extracellular DNAs (eDNAs) through various mechanisms, including autolysis and lateral gene transfer. These e-proteins are building blocks of biofilm present on the outer surface of a bacterial cell. They are secretory in nature and not only help in the formation of biofilm but also in the aggregation, initial attachment, and the formation of bacterial cell clusters [4]. The formation of biofilms is possible in both Gram-positive and Gram-negative bacterial species. However, there are high chances of the development of biofilm-associated infection, particularly in patients receiving treatment in the ICU and those who have medical device assistance. The primary sites for biofilm formation are natural surfaces like heart valves, teeth, lungs, and ears, as well as catheters and other medical devices and stents that trigger extracellular signals

[7]. These biofilms differ in structure, location, and the type of organism involved.

1. Medical Device-Associated Biofilms
2. Chronic Wound Biofilms
3. Dental Biofilms (Oral Biofilms)
4. Lung Biofilms
5. Urinary Tract Biofilms
6. Gastrointestinal Biofilms
7. Polymicrobial Biofilms

STAGES OF BACTERIAL BIOFILM FORMATION

Specific genes regulate the dynamic and continuous process of film synthesis, which involves various stages. The following are the different stages of bacterial biofilm formation, as presented in Fig.(1).




Fig. (1). Stages of bacterial biofilm formation (Step 1: Reversible Attachment; Step 2: Bacterial initial attachment and irreversible adhesion; Step 3: The extracellular matrix formation; Step 4: Microcolony formation; Step 5: Biofilm Maturation; Step 6: Biofilm Dispersal).

- Bacterial initial attachment and irreversible adhesion
- Extracellular matrix formation
- Microcolony formation
- Maturation of biofilm
- Dispersal of biofilm

Initial Attachment and Irreversible Adhesion

During an irreversible adhesion process, freely floating bacteria attach to a surface. Thereafter, bacterial cell proliferation occurs and other bacteria adhere to a site provided to them, leading to colonisation.

Co-Infections and Opportunistic Pathogens in Ameliorating Disease Outcomes

Rakesh Kumar^{1,*}, Vivek Raj², Vandana³, Biplab Pal¹ and Vikas Sharma¹

¹ School of Pharmaceutical Sciences, Lovely Professional University, Phagwara- 144411, Punjab, India

² Department of Biotechnology, Patna Women's College, Patna, Bihar, India

³ Indus Institute of Management, Indus University, Rancharda via Thaltej, Ahmedabad, Gujarat. 382114, India

Abstract: The clinical course of primary infections is frequently complicated by co-infections and opportunistic pathogens, which have a substantial impact on disease outcomes. Multiple pathogens can worsen illness severity, make identification more difficult, and reduce the effectiveness of treatment. Advanced molecular methods, such as polymerase chain reaction (PCR) and next-generation sequencing (NGS), are necessary for accurate diagnosis of co-infections because they can identify many pathogens at once and offer detailed insights into the microbial ecology. Treatment plans must be customized to target the particular infections after they have been discovered, taking into account the patient's immunological condition as well as any possible drug-drug interactions. Opportunistic infections, caused by pathogens that exploit weakened immune defenses, further complicate treatment. These infections often require a combination of antimicrobial therapies and immunomodulatory treatments to restore immune function and control pathogen proliferation. The interplay between co-infections and opportunistic pathogens necessitates a multidisciplinary approach, involving infectious disease specialists, microbiologists, and immunologists, to optimize patient outcomes. Advances in personalized medicine, including the use of biomarker-driven therapies and immune profiling, are showing promise in improving the management of co-infections. Early detection and targeted treatment are critical in preventing the progression of disease and reducing mortality rates. Future research should focus on understanding the mechanisms of pathogen interaction within the host and developing novel therapeutic strategies to mitigate the impact of co-infections and opportunistic pathogens on disease outcomes.

Keywords: Antimicrobial therapy, Co-infections, Disease outcomes, Diagnosis, Molecular techniques, Opportunistic pathogens.

* Corresponding author Rakesh Kumar: School of Pharmaceutical Sciences, Lovely Professional University, Phagwara- 144411, Punjab, India; E-mail:csrakeshk@gmail.com

Mukesh Kumar Singh, Gurdeep Singh, Amrendra Pratap Yadav & Papiya Bigoniya (Eds.)
All rights reserved-© 2026 Bentham Science Publishers

INTRODUCTION

Co-infections

Co-infections occur when a host is simultaneously infected by two or more distinct pathogens. These infections can be caused by a combination of viruses, bacteria, fungi, or parasites. Co-infections are of particular concern because they can complicate diagnosis, exacerbate symptoms, and affect treatment outcomes. The interaction between pathogens in co-infections can lead to either antagonistic or synergistic effects. In an antagonistic interaction, one pathogen may suppress the growth of another, potentially resulting in milder symptoms. Conversely, in a synergistic interaction, the pathogens may enhance each other's virulence, leading to more severe disease progression. Co-infections are common in conditions where the immune system is compromised or already weakened by a primary infection. For instance, individuals with HIV are often susceptible to co-infections such as tuberculosis (TB), as HIV weakens the immune system, increasing susceptibility to other pathogens [1]. Another common example is the co-occurrence of hepatitis B and C viruses in patients, which complicates liver disease management [2].

Co-infections can also occur in the context of viral epidemics and pandemics. For example, during the COVID-19 pandemic, co-infections with influenza and other respiratory pathogens were frequently observed, often worsening the clinical outcomes in affected patients [3]. In such cases, the presence of more than one pathogen can make treatment more complex, as the therapeutic strategies must account for multiple causative agents.

Opportunistic Pathogens

Opportunistic pathogens are microorganisms that usually do not cause disease in a healthy host but can lead to infections in individuals with weakened immune systems. These pathogens take advantage of certain conditions, such as a compromised immune system, disruptions in the normal microbial flora, or breaches in the body's physical barriers, like skin or mucosal membranes. Opportunistic infections are especially prevalent in immunocompromised individuals, such as those undergoing chemotherapy, organ transplant recipients on immunosuppressive drugs, or people living with chronic diseases like HIV/AIDS [4]. In such individuals, pathogens that are usually harmless or kept in check by a healthy immune system can cause serious infections. Common opportunistic pathogens include *Candida albicans*, which can cause fungal infections, and *Pseudomonas aeruginosa*, a bacterium responsible for respiratory and urinary tract infections. HIV/AIDS is a prime example of a condition where opportunistic pathogens become a significant concern. As the HIV attacks and

destroys CD4⁺ T cells, the immune system becomes progressively weaker, allowing various opportunistic pathogens, such as *Pneumocystis jirovecii* (which causes pneumonia) and Cytomegalovirus (which can lead to blindness or gastrointestinal diseases), to proliferate and cause severe infections [4].

Opportunistic pathogens can also arise in hospital settings, where patients are often vulnerable due to invasive procedures, immunosuppressive treatments, or prolonged antibiotic use. Hospital-acquired infections (HAIs), caused by opportunistic bacteria like *Staphylococcus aureus* and *Clostridioides difficile*, pose serious risks to patient health and can lead to outbreaks in healthcare settings [5].

The Epidemiological Significance

Co-infections and opportunistic pathogens play a crucial role in the epidemiology of human diseases, often complicating diagnosis, treatment, and outcomes. Co-infections occur when a host is simultaneously infected by two or more pathogens, which can interact in ways that exacerbate disease severity. Opportunistic pathogens, on the other hand, typically cause illness only when the host's immune system is weakened, such as in cases of immunodeficiency or chronic disease. The epidemiological significance of co-infections is particularly evident in diseases like HIV/AIDS, tuberculosis, and malaria. For instance, HIV-positive individuals are at an increased risk of contracting tuberculosis, a leading cause of death among those with HIV. Approximately one-sixth of the global population is affected by coinfections, involving over 270 pathogen taxa. These coinfections can alter infection dynamics and influence both individual and population-level disease outcomes [1, 47]. These co-infections can lead to more severe disease progression and complications due to immune system compromise. Similarly, malaria patients are often more susceptible to bacterial and viral infections, increasing morbidity and mortality rates [6]. Opportunistic pathogens, such as *Pneumocystis jirovecii* and *Candida albicans*, are another concern in immunocompromised populations, including those undergoing chemotherapy or organ transplantation. These pathogens take advantage of weakened immune defenses to cause life-threatening infections that would not typically occur in healthy individuals. For example, *Pneumocystis pneumonia* is a common cause of death in patients with AIDS, particularly in regions with limited access to antiretroviral therapy. In 2023, an estimated 8.2 million people were newly diagnosed with TB worldwide, up from 7.5 million in 2022. Co-infections with HIV, SARS-CoV-2, influenza, and various bacterial and fungal pathogens complicate TB management, especially in low- and middle-income countries (LMICs) [7, 48].

Unraveling the Complexities of Coinfection Diagnosis and Treatment

Monika Singh^{1,*}, Nitin Kumar², Sadish Kumar Shanmugam³ and Moumita Barman⁴

¹ Department of Pharmacology, I.T.S College of Pharmacy, Ghaziabad, India

² Department of Pharmacognosy, Meerut Institute of Technology, Meerut, India

³ Department of Pharmaceutical Chemistry, I.T.S College of Pharmacy, Ghaziabad, India

⁴ Department of Pharmaceutics, I.T.S College of Pharmacy, Ghaziabad, India

Abstract: Coinfections, characterized by the simultaneous presence of multiple pathogenic agents in a single host, pose significant challenges to accurate diagnosis and effective treatment. This chapter focuses on cases with overlapping clinical symptoms that obscure the identification of individual infections, emphasizing the need for a comprehensive diagnostic strategy. A multi-tiered approach integrating advanced imaging, biofluid analysis, and molecular techniques, particularly multiplex PCR assays, is discussed for detecting multiple pathogens in animal models. The complexity of coinfections is further highlighted by difficulties in treatment, including potential drug interactions and distinct resistance patterns. The chapter concludes by outlining essential steps for implementing advanced diagnostics and personalized therapeutic strategies to improve patient outcomes in cases of coinfection.

KEYWORDS: Coinfection, Diagnosis, Disease, Host response, Pathogenic agents, Treatment.

INTRODUCTION

When an individual has simultaneous infection with more than one pathogenic microorganism, it is known as coinfection. A typical scenario is for an individual to be infected with a virus (such as HIV) along with a bacterium like *Mycobacterium tuberculosis* or two different viral infections concurrently, such as HIV and hepatitis C [1].

* Corresponding author Monika Singh: Department of Pharmacology, I.T.S College of Pharmacy, Ghaziabad, India; E-mail: monikas@its.edu.in

However, in medicine, it is the trickiest of all because you are not talking about one but many infecting agents, interacting amongst themselves and with the host response. Coinfections can dramatically change the progression, virulence, and remediate response of the involved diseases, making them a vital area in all clinical and research fields [2].

Coinfections frequently manifest with overlapping symptoms, so identifying all of the associated pathogens can be difficult. For example, an individual with a viral respiratory infection and a bacterial respiratory infection can sometimes have fever, cough, and fatigue, making the clinical assessment of these symptoms challenging. The combined effects of multiple pathogens may lead to a greater viral or bacterial disease burden. For example, a patient with influenza and bacterial pneumonia may experience greater respiratory distress than a patient with influenza or another type of pneumonia [3, 4].

One pathogen involved in a coinfection may modulate the immune response of the host in ways that may facilitate or impair the establishment of the second pathogen. For example, some viruses can suppress immune responses, which may allow for easier bacterial infection. Pathogens can compete for the same resources of the host, such as nutrients [5], or utilize host cells that share cellular receptors. This competition can determine which pathogen is most likely to become dominant or how severe the infectious stage will be. Some pathogens may make changes to the host physiology or the surrounding environment, which may influence other pathogens' survival or multiplication. For instance, a bacterial infection may lead to tissue destruction, which will provide access to another pathogen. In treating diseases, there are a number of complexities, including drug interactions. Some drugs for one infection may interact with those for the other and may hence reduce their effectiveness or increase the chances of side effects. The identified comorbid bacterial infections also amplify the extent of antibiotic resistance, especially if broad-spectrum antibiotics are used without necessarily testing for all the bacteria. It may cause the infections to be trickier to control, treat, and contain [6]. The transmission of coinfections is not limited to single infections, as they appear more complicated. For instance, one pathogen may enhance the effects of another, as observed with HIV, which makes one more vulnerable to the rest of the STIs. Completing the coinfecting patients' history and clearly identifying all pathogens in patients are complicated tasks in public health systems, especially in regions with the presence of multiple infectious diseases [7]. In many cases, control measures take time because the different pathogens require concerted efforts, which can cost a lot of money. Consequently, coinfections are highly applicable in global health since they infect persons who have little or no access to health facilities. Managing coinfections is critical in enhancing the health status of those regions [8].

It can be concluded that coinfection is a very complicated process that interrelates several pathogens in one host. Such interactions can profoundly change the development of diseases, the difficulty of their diagnosis and treatment, and the hindrances experienced in the field of public health. The knowledge of and approaches to coinfections are a focal research aspect that has significant implications for single-patient care on global fitness [9].

EPIDEMIOLOGY OF COINFECTIONS

• Prevalence of Coinfections

Compromised Immune Systems: Immunocompromised persons are at high risk of developing other infections. Their immune system is not as strong, and thus, they find it difficult to combat several diseases. For instance, people living with HIV are more prone to infections, including TB, fungal infections, and viral infections such as hepatitis [10].

Endemic Regions: Another factor is that coinfections also occur in areas where some infectious diseases are comparatively more prevalent. For instance, in Sub-Saharan Africa, malaria, TB, and HIV are communicable diseases; the diseases frequently occur at the same time. It should, however, be noted that these regions have environmental, socio-economic, and healthcare conditions that allow for the proliferation of multiple pathological agents [11].

• Patterns of Coinfections

- **HIV and Tuberculosis (TB):** HIV weakens the immune system, allowing latent TB infections to become active, making this coinfection particularly dangerous [12].
- **HIV and Malaria:** Malaria can worsen HIV infection by increasing viral replication, and HIV weakens the immune response to malaria, leading to more severe illness [13].
- **Helminth Infections and Malaria:** In tropical regions, helminth (parasitic worm) infections are common and can coexist with malaria. These interactions can lead to more severe anaemia and immune dysregulation [14].
- **COVID-19 and Respiratory Infections:** During the COVID-19 pandemic, many patients experienced coinfections with other respiratory pathogens like influenza or bacterial pneumonia, which compounded the severity of the illness [15].

• Impact of Coinfections

- **Increased Disease Severity:** Coinfections can make diseases more severe. For example, people suffering from both malaria and HIV experience severe malaria symptoms [16].

Novel Drug Delivery Systems to Combat Antimicrobial Resistance

Sanjay Kumar Gupta^{1,*}, Astha Verma², Akash Gupta¹, Sumit Sahu¹, Nousheen Khatoun¹, Anjila Firdous¹ and Mohammad Adnan Raza¹

¹ Department of Pharmacology, Rungta College of Pharmaceutical Sciences and Research, Chhattisgarh– 490024, India

² Department of Pharmaceutics, Shri Rawatpura Sarkar Institute of Pharmacy, Chhattisgarh, – 490024, India

Abstract: Antimicrobial resistance (AMR) poses a major threat to global health, as infections remain a leading cause of death worldwide. With few new antibiotics being developed, researchers are turning to innovative delivery methods for existing drugs to combat AMR. The novel carriers contribute several advantages over conventional antibiotic administration methods, including enhanced solubility, improved stability, increased permeability through cellular barriers and into bacterial biofilms, higher bioavailability, extended drug half-life, targeted delivery to specific tissues, and even the ability to bypass bacterial efflux pumps that contribute to resistance. Novel carriers such as liposomes, polymeric nanoparticles (PNPs), nanoemulsions, dendrimers, carbon nanotubes, and metal nanoparticles have emerged as promising solutions, offering the potential to create sophisticated drug delivery systems in the form of antibiotic-carrying nanoparticles. Other promising approaches, including the development of stimuli-responsive drug delivery systems, combination therapies within a single delivery system, advanced surface modification techniques, and biological delivery vehicles like bacteriophages and extracellular vesicles, are being engineered to deliver antibiotics directly to specific bacterial species. Additionally, 3D-printed drug delivery devices, smart hydrogels, and implantable devices are also being developed to treat biofilm-associated infections. While many are still in developmental stages, these novel approaches offer significant potential to revitalize existing antibiotics, overcome resistance mechanisms, and provide more effective treatments for bacterial infections in the face of growing AMR.

Keywords: 3D printed drug delivery, Antimicrobial resistance, Multidrug-resistant, Novel carriers, Resistance mechanisms, Smart hydrogels.

* Corresponding author Sanjay Kumar Gupta: Department of Pharmacology, Rungta College of Pharmaceutical Sciences and Research, Chhattisgarh– 490024, India; E-mail: sanjay.gupta0311@gmail.com

Mukesh Kumar Singh, Gurdeep Singh, Amrendra Pratap Yadav & Papiya Bigoniya (Eds.)
All rights reserved-© 2026 Bentham Science Publishers

INTRODUCTION

Overview of Antimicrobial Resistance (AMR)

Increased mortality and long-standing infections related to antimicrobial resistance have become a global health crisis by killing the effectiveness of conventional antibiotics. In this regard, the challenge posed by AMR needs some innovative solutions. Some new drug delivery systems have been developed, which hold promise for antimicrobial drugs. The present paper focuses on recent developments in the field of novel drug delivery systems (NDDSs) to improve the delivery and efficacy of antimicrobial agents [1]. The current review has discussed several approaches that include nanotechnology-based carriers, liposomes, polymeric nanoparticles (PNPs), and dendrimers. Some of these particles are considered very promising in infectious disease treatment due to their ability to cross biological barriers and target the pathogen with minimized mechanisms of drug resistance [2]. The critical areas addressed in this respect include enhancement of drug solubility, stability, and bioavailability, as well as controlled release and targeted delivery to infection sites. The strategies have also been elaborated in detail relating to the combination of NDDS with antimicrobial peptides and smart systems responsive to environmental stimuli [3]. Considering the synergistic potential in conjunction with current antimicrobial therapy, which may mitigate AMR, NDDS has the potential to transform the future treatment landscape of infectious diseases. Accordingly, future research directions and clinical translation of these technologies are critically examined to address the multifaceted challenges posed by AMR [4].

Antibiotics, also called “*antimicrobial agents*”, are chemical substances made by a microorganism that kill or slow the growth of another microorganism. The development of resistant microorganisms and their resistance mechanisms, since the discovery of antimicrobial drugs in 1937, has given rise to the idea of AMR [5]. Another characteristic of infection-causing bacteria that contributes to the explanation of AMR is their resistance to the effects of antimicrobial drugs, which either stop their growth or eliminate them. There are additional aspects to this ailment as well, like substantial medical costs, frequent examinations, and subsequent visits. Due to the innate capacity of resistant bacteria to survive, mutate, and adapt to resistance to stress and increased exposure to antimicrobial chemicals, antibiotic-resistant bacteria are an inevitable part of the evolutionary process [6]. In 2001, the World Health Organization (WHO) established the Global Strategy for Containment of AMR and defined the appropriate use of antimicrobials as “cost-effective use of antimicrobials which maximizes clinical therapeutic effect while minimizing drug-related toxicity and the development of antimicrobial resistance” [7]. Antibiotic-resistant bacteria and ARGs can be found

in the environment, which can also act as an incubator for resistance. Consequently, it is the predominant means of dispersing resistant bacteria associated with fecal matter in water, sewage systems, and organic fertilizers(8).

AMR refers to the ability of microorganisms, which include bacteria, viruses, fungi, and parasites, to resist the therapeutic effects of medications that were previously effective in fighting them. This phenomenon reduces the effectiveness of drugs such as antibiotics and antivirals, which raises morbidity, mortality, and healthcare costs [9]. Combating AMR has become a critical global health priority that demands immediate and coordinated action from legislators, medical professionals, academics, and the general public. When bacteria, viruses, fungi, and parasites resist antimicrobial drugs, traditional treatments become ineffective, and the risk of infection rises. Although AMR is a naturally occurring phenomenon, in recent decades, human influences have greatly accelerated and aggravated its advancement [10].

Current Challenges in Treating Resistant Infections

Antibiotic resistance in multidrug-resistant (MDR) pathogens, such as Methicillin-Resistant *Staphylococcus aureus* (MRSA), *Vancomycin-resistant Enterococci* (VRE), and Carbapenem-resistant Enterobacteriaceae (CRE), has reduced treatment choices and raised death rates. The creation of biofilms increases treatment complexity by conferring up to 1,000-fold resistance on microorganisms. Additionally, bacteria lessen the efficiency of antibiotics by using β -lactamases and efflux pumps [11]. The paucity of novel antibiotics and inadequate medication penetration into hard-to-reach regions hampers the treatment of resistant diseases. Inadequate dosage and prolonged antibiotic exposure also contribute to the development of resistance during therapy, favouring resistant bacteria [12].

Limitations of Current Systems

Such limitations add to the more general difficulties in managing resistant infections, such as the rise of microorganisms that are MDR, the development of biofilms that impede therapy, and a notable decrease in the discovery of novel medicines. These elements work together to highlight the critical need for creative solutions, such as new drug delivery methods, to increase the effectiveness of antibiotics, target resistant bacteria, and boost treatment results [13].

SUBJECT INDEX

A

Absorption 80
 Accelerated wound healing and localized infection 191
 Access control lists (ACLs) 38
 Acid-sensitive chemical bond 132
 Acid-sensitive linkages 132
 Acinetobacter baumannii 59, 79, 82, 164, 197
 Acquired immunodeficiency syndrome (AIDS) 148
 Active drug efflux 186
 Adhesion of nanoparticles 131
 Adjuvants 182, 183
 Adsorption mechanisms 127
 Advanced diagnostics 168
 Advanced molecular methods 140
 Adverse effects 55, 57, 62, 78, 112, 169, 181, 183, 208
 Aeruginosa 8, 60, 123, 148, 197, 200
 Aggregation 123
 Aggressive treatment 148, 168, 170
 Alginate 123, 198
 Altered metabolism 204
 Altered microenvironment 129
 Amikacin 60, 107
 Aminoacyl-tRNA 62
 Aminoglycosides 48, 49, 58, 59, 63, 73, 74, 83, 107, 186
 Amoxicillin 7, 54, 55, 74, 107, 111
 Amphiphilic polycarbonates 196
 Antigenic variation 15, 38
 Antimicrobial peptide PLG0206 207
 Antimicrobial peptides (AMPs) 40, 48, 49, 76, 81, 83, 113, 115, 202, 203, 209
 Antimicrobial pharmacotherapies 169
 Antimicrobial stewardship 169, 207
 Antimicrobial tolerance 206
 Antiretrovirals 152, 170
 Arsphenamine 50
 ATP-binding cassette 186
 Atypical mycobacterial infections 65

Autoinducers 125

Azithromycin 67, 73, 75, 106, 197

B

Bacillus anthracis 2, 27, 31, 33
 Bacillus calmette-guérin (BCG) 5
 Bacterial biofilm development 125
 Bacterial cellular envelope 184
 Bacterial homeostasis 127
 Bacterial pathogenesis 1, 14, 16, 17, 28
 Bacterial RNA polymerase 75
 Bacterial type II topoisomerases 69
 Bacteriophages 10, 40, 114, 153, 171, 178, 187, 191
 Bacteriostatic 100, 109, 112
 Bacteroides fragilis 70
 Beta-lactamase (β -lactamase) 57, 127, 180, 181, 183, 202
 Beta-lactams (β -lactams) 48, 49, 53, 55, 73
 Binary fission 23, 24
 Bioavailability 178, 179, 182, 184, 189, 198, 203
 Biocompatibility 191, 197, 198, 199, 202
 Biodegradability 191, 197, 198
 Bioengineering 122, 131
 Biofilm antimicrobial tolerance 206
 Biofilm dispersal 124, 125
 Biofilm heterogeneity 205
 Biofilm maturation 124, 125, 129
 Bioinformatics 40
 Biological delivery vehicles 178
 Bioluminescent assays 126
 Biomaterials 200, 203
 Biomedical nanotechnology 132
 Blood-brain barrier (BBB) 192, 194
 Bordetella pertussis 34, 36, 67
 Borrelia burgdorferi 28, 33, 64
 Broad-spectrum antibiotics 7, 61, 68, 77, 78, 82, 107, 109, 111, 112, 114, 161
 Burkholderia pseudomallei 35

C

Candida albicans 141, 142, 148, 187, 200
 Carbapenem-resistant enterobacteriaceae (CRE) 9, 79, 81, 180, 208
 Carbapenems 49, 53, 57, 58, 60, 83, 107, 113
 Carbon nanotubes (CNTs) 178, 191, 196
 Ceftazidime-avibactam 81, 113
 Cellular uptake 61, 190, 197
 Cephalosporins 51, 53, 55, 56, 57, 74, 83, 106
 Charge-shifting approaches 132
 Chemical vapor deposition (CVD) 197
 Chlamydomydia pneumoniae 63, 67, 70
 Chloramphenicol 52, 73, 75
 Chromosomal segregation 69, 75
 Ciprofloxacin 70, 74, 75, 107, 133
 Clarithromycin 68, 80, 106
 Clostridioides difficile 68, 82, 112, 142, 149
 Colistin 73, 76
 Community-acquired pneumonia (CAP) 55, 56, 63, 67, 72, 77
 Confocal laser scanning microscopy (CLSM) 125, 126
 Congo red agar (CRA) 126
 Controlled release mechanisms 113, 128, 134, 179, 183, 184, 191, 193, 195, 198, 200, 209
 Corynebacterium diphtheriae 14, 34, 37
 CRISPR-cas antimicrobials 16, 83
 Cryo-electron microscopy 53, 69, 71, 75
 Cystic fibrosis 36, 60, 67, 83, 130, 148
 Cytokine storms 30, 39, 149, 167, 168
 Cytotoxicity 191, 196, 199, 200

D

Daptomycin 49, 76, 111
 De-escalation 58, 78, 84, 112
 Dendrimers 178, 179, 191, 199, 208, 209
 Deoxyribonucleic acid (DNA) 22, 23, 48, 68, 69, 71, 74, 75, 100, 107, 112, 122, 186, 187, 196
 Diagnostic sensitivity 168
 Dihydrofolate reductase (DHFR) 71
 Dihydropteroate synthase (DHPS) 71
 DNA gyrase 68, 69, 75
 Doxycycline 7, 61, 62, 63, 64, 65, 66, 73, 107, 202
 Drug efflux 189

E

Efflux pumps 63, 67, 123, 127, 178, 180, 182, 183, 186, 187, 189, 194, 206
 Electrostatic interactions 196, 199
 Empiric therapy 55, 58, 59, 72, 77, 78, 84
 Endocytosis 14
 Endotoxins 14, 37, 39, 135
 Enzymatic inactivation 63, 67
 Enzyme-responsive systems 133, 202
 Epstein-barr virus (EBV) 166, 167
 Eravacycline 61
 Erythromycin 7, 53, 68, 73, 75, 106
 Extended-spectrum beta-lactamase (ESBL) 8, 57, 59, 60, 72, 207
 Extracellular polymeric substance (EPS) 122, 123, 125, 129, 130, 131

F

Fecal microbiota transplantation (FMT) 149
 Field-responsive systems 132, 135, 203
 Fidaxomicin 68, 75, 149
 Fluoroquinolones 68, 74, 75, 107
 Folic acid production 71, 74, 107

G

Genetic plasticity 186
 Genome sequences 82
 Genomics 16, 28, 82, 113, 152, 153
 Gentamicin 55, 59, 60, 73, 74, 83, 107, 197, 198, 201
 Germ theory 2, 3, 4, 26, 27
 Gram-negative bacteria 7, 8, 13, 14, 37, 56, 57, 58, 59, 60, 61, 69, 70, 72, 73, 76, 83, 123, 148, 184, 185, 186, 189
 Gram-positive bacteria 7, 11, 13, 22, 37, 49, 54, 56, 59, 66, 67, 70, 73, 76, 80, 106, 107, 111, 186

H

Haemophilus influenzae 6, 28, 31, 38, 64, 67, 70
 Helicobacter pylori 12, 37, 65, 67, 80, 145, 202
 Hemophagocytic lymphohistiocytosis (HLH) 167

Hepatitis C virus (HCV) 145, 164
Horizontal gene transfer (HGT) 128, 187
Host-directed therapies (HDTs) 170, 171
Human immunodeficiency virus (HIV) 141, 142, 143, 144, 145, 146, 147, 148, 150, 151, 153, 160, 162, 163, 164, 165, 166, 167, 169, 170, 171
Hyaluronidase-responsive systems 133
Hydrogels 123, 135, 178, 191, 199, 200, 208
Hypoxia-responsive systems 133, 134

I

Immune dysregulation 145, 162, 167, 168, 171
Immune exhaustion 145, 150, 167
Immunomodulatory properties 62, 65, 81, 83
Infectious diseases society of america (IDSA) 63, 77
Inhibition of matrix metalloproteinases 62, 64
Intracellular pathogens 14, 67, 70, 72, 115, 184
Iron oxide polymersomes (IOPs) 201

K

Klebsiella pneumoniae 59, 70, 197
Koch's postulates 2, 4, 27

L

Lefamulin 80
Legionella pneumophila 28, 34, 63, 67, 70, 72
Levofloxacin 70, 75, 81, 107, 198
Ligand-receptor interactions 183
Linezolid 9, 49, 51, 73, 107, 111, 113
Lipid-based nanocarriers 197, 208
Lipopolysaccharides (LPS) 14, 15, 22, 37, 38, 76, 185, 195
Liposomes 131, 132, 136, 178, 179, 182, 183, 190, 193, 194, 195, 197, 200, 201, 202, 208, 209

M

Macrolides 7, 51, 63, 66, 67, 68, 73, 75, 106
Magnetic field-responsive systems 134, 135, 200, 201, 202, 203, 204
Magnetic resonance imaging (MRI) 105, 203

Matrix metalloproteinases (MMPs) 62, 64, 133
Mesoporous silica 192
Metagenomics 153
Methicillin-resistant staphylococcus aureus (MRSA) 3, 9, 49, 56, 73, 78, 80, 82, 106, 107, 164, 171, 180, 208
Minimum bactericidal concentration (MBC) 201
Minimum inhibitory concentration (MIC) 127, 130, 198
Minocycline 64, 65, 66, 107
Molecular diagnostics 167, 168
Moxifloxacin 70, 80, 107
Multidrug resistance (MDR) 8, 56, 57, 58, 59, 60, 72, 73, 76, 79, 81, 83, 84, 107, 130, 180, 182, 183, 186, 208
Mycobacterium tuberculosis 2, 5, 21, 27, 28, 32, 36, 38, 69, 70, 145, 160, 208

N

Nanomedicine 114
Nanotechnology-based drug delivery systems 113, 115, 122, 128, 131, 132, 136, 178, 179, 189, 190, 191, 194, 195, 196, 201, 208
Neisseria meningitidis 28, 32, 36, 37, 38
Next-generation sequencing (NGS) 82, 111, 140, 153, 172

O

Opsonization 15, 39
Oxazolidinones 49, 51, 73, 75, 107, 111
Oxidative stress 125, 144

P

Pathogen-associated molecular patterns (PAMPs) 38
Pattern recognition receptors (PRRs) 38
Penicillin-binding proteins (PBPs) 53, 55, 57, 186
Peptidoglycan 11, 22, 38, 53, 54, 55, 73
Periprosthetic joint infections (PJIs) 207
Persistent infections 114, 130, 145, 181, 194, 206, 209
pH-responsive delivery systems 132, 201, 202

Phage therapy 10, 28, 48, 49, 81, 83, 113, 114, 171, 191

Pharmacogenomics 79, 82, 112

Photothermal 134, 201

Plasmodium falciparum 64, 147

Polymerase chain reaction (PCR) 78, 111, 140, 160, 165, 169

Polymeric nanoparticles (PNPs) 178, 179, 190, 196, 198, 208

Pseudomonas aeruginosa 36, 54, 56, 59, 70, 72, 79, 80, 141, 148, 197, 199, 208

Q

Quantum dots (QDs) 191

Quorum sensing (QS) 16, 21, 66, 123, 125, 128, 135, 189, 206

R

Reactive oxygen species (ROS) 69, 131, 134, 135, 190, 191

Resistance-nodulation-division family 186

Ribosomal protection proteins 63, 186

RNA synthesis 73, 75

S

Sepsis and septic shock 6, 15, 30, 35, 37, 39, 59, 77, 78, 100, 101, 102, 105, 107, 112, 171

Solid lipid nanoparticles (SLNs) 191, 197

Staphylococcus aureus 12, 29, 30, 36, 37, 38, 39, 52, 54, 67, 70, 133, 135, 163, 169, 197, 198, 199

Stimuli-responsive drug-delivery 122, 128, 132, 134, 135, 136, 178, 179, 200, 202, 203

Streptococcus pneumoniae 6, 15, 28, 30, 31, 32, 36, 38, 54, 67, 70, 114

Sulfonamides 7, 49, 71, 72, 74, 107, 186

Superparamagnetic iron oxide nanoparticles (SPIONs) 201

Surface modification techniques 131, 178, 191, 198

Synthetic minority oversampling (SMOTE) 45, 46, 47, 48, 166

Systemic inflammatory response syndrome (SIRS) 30

T

Temperature-responsive system 135

Tetracyclines 7, 48, 51, 52, 53, 61, 62, 63, 64, 65, 66, 73, 74, 75, 107

Theranostic capabilities 191, 202

Tobramycin 60, 74, 107, 135, 197, 208

Topoisomerase IV 68, 69, 75

Transcriptional initiation 75

Trimethoprim-sulfamethoxazole 72, 74, 107

U

Urinary tract infections (UTIs) 12, 14, 32, 36, 56, 59, 60, 104, 107, 141, 189

V

Vancomycin-resistant enterococcus (VRE) 9, 49, 107, 180, 208

Vibrio cholerae 5, 12, 14, 27, 32, 36, 37

W

Whole-genome sequencing 16

Z

Zinc oxide nanoparticles (ZnO NPs) 49, 196, 200

Zoonotic bacterial infections 30, 31, 33, 34, 35



Mukesh Kumar Singh

Dr. Mukesh Kumar Singh is an Associate Professor at the School of Pharmaceutical Sciences, Faculty of Pharmacy, IFTM University, Moradabad, Uttar Pradesh, India. He holds an M.Pharm. in Pharmaceutical Biotechnology from SRM College of Pharmacy, SRM Institute of Science and Technology, and a Ph.D. in Pharmaceutical Sciences from CSVTU, Bhilai. With over 16 years of experience in pharmaceutical education and research, he has published 55+ research and review papers, 10 book chapters with leading publishers, and 10 patents. He has guided numerous doctoral and postgraduate students and is a member of the Association of Pharmaceutical Teachers of India. Dr. Singh also serves as an active reviewer for national and international journals.



Gurdeep Singh

Dr. Gurdeep Singh is a Professor at the School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, with over 16 years of academic and research experience. He holds a B.Pharm., M.Pharm. in Pharmaceutical Chemistry, and Ph.D. in Pharmaceutical Sciences from reputed Indian institutions. He has successfully guided over 30 M.Pharm. and 7 Ph.D. scholars and has published more than 65 research and review articles in national and international peer-reviewed journals. Dr. Singh holds five patents, is the author of Biostatistics and Research Methodology, and has contributed book chapters to publishers including Bentham, Elsevier, Wiley, and Springer. A recipient of the Young Scientist Award and Dynamic Professional Award, he is a life member of APTI and IPGA. His research interests focus on the design and synthesis of novel antidiabetic and anticancer agents.



Amrendra Pratap Yadav

Dr. Amrendra Pratap Yadav is a Professor at Meerut Institute of Technology, Meerut, Uttar Pradesh, India, with 16 years of experience in pharmaceutical education and research. He holds B.Pharm., M.Pharm., PGDCA, and Ph.D. degrees and qualified GPAT-2013. He is a life member of the Association of Pharmaceutical Teachers of India (APTI) and the Indian Pharmaceutical Association (IPA). His research interests include pharmaceutical biotechnology and the development of novel drug delivery systems. Dr. Yadav has published 16 research articles, contributed three book chapters, and holds two patents. He has presented his work at numerous national and international conferences. His contributions to academia have been recognized with the Best Teacher Award (2015) and the Inspirational Associate Professor Award (2021). He has successfully supervised two Ph.D. scholars.



Papiya Bigoniya

Dr. Papiya Bigoniya is a Certified Toxicologist and Fellow of the Academy of Toxicological Sciences (ATS, USA), with over 28 years of experience in academia, research, and regulatory consultancy. She holds a PhD in Pharmaceutical Sciences, along with advanced qualifications in Pharmacology, Cancer Biology, Public Health, and Pharmaceutical Management. Dr. Bigoniya has authored over 130 peer-reviewed publications, delivered more than 50 expert lectures, and received numerous national and international awards for her contributions to drug safety, toxicology, and pharmacovigilance. Her expertise in regulatory guidelines, including ICH and GCP, makes her a respected researcher, trainer, and consultant in pharmaceutical sciences.